Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

Safety and Efficacy of AM712 in Patients with NAMD

ClinicalTrials.gov ID: NCT05345769

Public ClinicalTrials.gov record NCT05345769. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 24, 2026, 11:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Multi-Center, Open-label, Sequential, Multiple Ascending-Dose and High Concentration Cohorts Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AM712 Following Intravitreal Administration in Patients with Neovascular Age-related Macular Degeneration.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this Phase 1 study is comprised of multiple ascending-dose component (Part 1) and high concentration component (Part 2) to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in patients with neovascular age- related macular degeneration (nAMD).

Study identification

NCT ID
NCT05345769
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
AffaMed Therapeutics Limited
Industry
Enrollment
21 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 27, 2022
Primary completion
Nov 3, 2024
Completion
Nov 3, 2024
Last update posted
Dec 11, 2024

2022 – 2024

United States locations

U.S. sites
9
U.S. states
6
U.S. cities
9
Facility City State ZIP Site status
Retina Consultants San Diego Poway California 92064 —
Bay Area Retina Associates Walnut Creek California 94598 —
Colorado Retina Lakewood Colorado 80228 —
Florida Eye Associates Melbourne Florida 32901 —
Retina Research Institute at New England Retina Consultants Springfield Massachusetts 01107 —
Tennessee Retina, PC Nashville Tennessee 37203 —
Retina Consultants of Texas Bellaire Texas 77401 —
Retina Consultants of Texas San Antonio Texas 78240 —
Retina Consultants of Texas The Woodlands Texas 77384 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05345769, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 11, 2024 · Synced Sep 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05345769 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →